Stay updated on Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial
Sign up to get notified when there's something new on the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page.

Latest updates to the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page
- Check6 days agoChange DetectedThe page now includes the Arm I dosing schedule and treatment duration, MRI/blood collection procedures, and lists a participating site, plus the addition of MTD/RP2D and EFS endpoints, quality-of-life measures, and other trial details.SummaryDifference0.3%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded recruitment status notice 'No longer looking for participants' and new help/navigation sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') along with a page revision indicator 'Revision: v3.6.0'. Adjusted the heading from 'Intervention / Treatment' to 'Intervention/Treatment' and removed the older revision tag 'Revision: v3.5.5'.SummaryDifference0.2%

- Check27 days agoChange DetectedRevision from v3.5.4 to v3.5.5 indicates a minor metadata update to the page, with no apparent changes to study details.SummaryDifference0.0%

- Check48 days agoChange DetectedA new 'Sample Collection' entry was added on 2026-05-13, and the study documentation was updated to Revision: v3.5.4 on 2026-05-12, replacing Revision: v3.5.3.SummaryDifference0.1%

- Check70 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance release of the site rather than any change to the clinical trial record content.SummaryDifference0.0%

- Check77 days agoChange DetectedAdded 2026-04-13 Revision: v3.5.2 and removed 2026-04-08 Revision: v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page.